Connect with us

Business

Is Canada (finally) going to allow CBD to be sold in mainstream retail?

Published

on

A watershed CBD recommendation expected this summer from Canadian health authorities could resolve one of the oddest differences between the cannabis industries in Canada and the U.S. – their starkly different approaches to hemp extracts.

In the United States, hemp is legal and broadly available, while higher-THC cannabis remains an illicit drug on the federal level – despite broad disregard for marijuana prohibition by state governments.

The Canadian government, by contrast, legalized high-THC cannabis in 2018.

But CBD remains a controlled substance in Canada, regulated in a similar manner to high-THC marijuana.

Canada’s CBD sellers commonly operate in the illicit market because of federal rules requiring CBD sales to occur in provincially licensed stores, which tend to specialize in high-THC products and aren’t able to import U.S.-made CBD for commercial purposes.

But Canada’s stifled CBD market could soon be opening up.

That’s because Health Canada, which oversees both pharmaceutical drug sales and the nation’s high-THC cannabis industry, is expecting final recommendations this summer on CBD and what it calls “health products containing cannabis that would not require practitioner oversight.”

A three-year review by a Health Canada advisory committee is expected to conclude this summer with “appropriate safety, efficacy and quality standards” for those products, agency spokesperson Tammy Jarbeau told MJBizDaily.

Jarbeau could not say how long it might take the agency to make a decision on CBD sales after the release of the recommendation.

If it all leads to market opportunities outside the nation’s marijuana retailer sector, Canada could see a huge new market open to cannabis as well as mainstream businesses.

“The opportunity is significant” for a vibrant CBD market outside traditional cannabis retailers, said Bethany Gomez, managing director of the Brightfield Group, a cannabis-focused consumer-research firm in Chicago.

“Canadian regulations have been a huge barrier to the CBD category gaining traction. If the regulations change, there’s a real opportunity for significant growth for CBD.”

According to Sean Karl, a Vancouver, British Columbia-based supply-chain consultant who specializes in cannabis logistics, many mainstream Canadian retailers are eager to start selling CBD.

He used a hockey term to describe the way retailers there want to carefully maneuver to maximize profit without violating any restrictions set by health authorities.

“Everyone’s trying to stickhandle through the regulations,” he said.

Why Canada started slow

Canadian regulators say they want more information on over-the-counter CBD before allowing it, and retailers have largely complied.

That has prevented a national market for hemp extracts from taking off.

CBD products can be found in some of Canada’s 3,000 or so cannabis retailers.

But the cannabinoid can’t be found legally in convenience or grocery channels.

None of Canada’s 13 provinces or territories maintain hemp laws that contradict those of national authorities.

Among Canada’s 74 approved hemp cultivars, only a handful produce enough CBD for commercial viability.

Extracting CBD from a hemp cultivar bred for its fiber or grains is possible but is “kind of a money-losing operation,” said Deepank Utkhede, a Canadian native and chief operating officer at Vantage Hemp, a cannabinoid manufacturer in Greeley, Colorado.

“It’ll almost cost more to extract it than you’re going to get for it,” Utkhede explained.

Meanwhile, Canadian import restrictions have prevented the nation’s product manufacturers from tapping cheap wholesale CBD supplies in the U.S.

With limited exceptions for medical and research use, Canada doesn’t allow foreign-made CBD into the country.

Because of those CBD limitations, cannabis entrepreneurs in Canada have almost exclusively gone after existing cannabis users, who are interested mostly in THC profiles, Gomez said.

“Canada has not successfully wooed over people who were not high-THC cannabis users before,” she said.

“In the U.S., CBD was everywhere in 2019. Celebrities were all talking about it. It was in every headline.

“In Canada, businesses were much more focused on legacy cannabis users.”

Different story in the U.S.

Things have gone differently for CBD in the United States.

For years now, U.S. health regulators have been making the same arguments as their northern colleagues, saying there isn’t enough research on CBD to allow it to be sold outside pharmaceutical channels.

The difference?

Despite those health warnings, retailers in all 50 U.S. states can be found selling over-the-counter CBD anyway.

From head shops to hair salons, yoga studios to farmers’ markets, thousands of CBD products are openly sold and promoted. Gummies, tinctures and capsules are especially popular.

Some U.S. retailers point to contradictory state laws regarding hemp extracts to justify sales.

Others simply ignore health regulations at all levels of government and hope that the federal legality of low-THC hemp plants equates to low legal risk from selling extracts from those plants. It’s a cavalier business approach that has worked with few exceptions.

Indeed, lax enforcement of unapproved CBD use in the United States has emboldened hemp operators to experiment with further manipulating extracts to produce intoxicating isomers such as delta-8 THC and HHC. (HHC, short for hexahydrocannabinol, is a hemp derivative occurring naturally in small quantities in the plant.)

Perhaps ironically, those intoxicating hemp products are most widely available in states that don’t yet allow products made from naturally occurring THC.

Northern hope

Hemp businesses making CBD aren’t just hoping Canada will open new sales opportunities.

Some are counting on Canada to correct some of its southern neighbor’s mistakes.

American CBD manufacturers struggle to position themselves as quality brands when U.S. health authorities repeatedly decry CBD as unsafe but then do little to take low-quality products off shelves.

Among those companies is Charlotte’s Web Holdings, a Colorado-based CBD maker that holds more than 3% of the $5 billion American CBD market in 2022, the largest share of any U.S. manufacturer, according to Brightfield sales data.

Charlotte’s Web has been working since 2019 to have a proprietary CBD-rich cannabis variety approved to be grown in Canada, partnering with Canadian producers to avoid import restrictions.

That cultivar was approved last year, making 2022 the first full growing season.

(Charlotte’s Web actually can get some of its CBD products imported into Canada, via one of the rare exceptions for medical use. But the exemption applies only to a small number of patients and doesn’t allow Charlotte’s Web to sell CBD to new Canadian users.)

Charlotte’s Web Chief Operating Officer Jared Stanley said his company has been preparing for years to begin widespread Canadian sales and sees potential benefits from Canada’s careful CBD approach.

“My hope for Canada is that they don’t make the same mistake that U.S. made,” Stanley told MJBizDaily.

“(The U.S.) legalized the category, then we allowed it to be marginalized into lollipops at gas stations.

“We want to see a market open up in Canada that keeps the highest level of quality control and consistency to the consumers.”

Gomez acknowledged that a potential CBD market in Canada would open under far different market conditions than those seen in the U.S. in the heady months after hemp cultivation was legalized via the 2018 Farm Bill.

“It’s not the latest new health ingredient anymore,” she said. “Canadians may be a bit less motivated to go try it.”

That doesn’t deter CBD makers.

“What we see in Canada is a great opportunity for the category,” Stanley said.

Source: https://mjbizdaily.com/when-will-canada-allow-cbd-to-be-sold-in-mainstream-retail-stores/

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News